News
VVOS
0.0822
-16.12%
-0.0158
Reported Earlier, Vivos Therapeutics Q3 EPS $(0.07) Beats $(0.42) Estimate, Sales $6.414M Beat $5.937M Estimate
Benzinga · 4h ago
Vivos Therapeutics GAAP EPS of -$0.07 beats by $0.25, revenue of $6.41M beats by $0.94M
Seeking Alpha · 5h ago
Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 10h ago
*Vivos Therapeutics 3Q Loss/Shr 7c >VVOS
Dow Jones · 10h ago
*Vivos Therapeutics 3Q Rev $6.41M >VVOS
Dow Jones · 10h ago
Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 22h ago
Weekly Report: what happened at VVOS last week (1109-1113)?
Weekly Report · 1d ago
Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 4d ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11/09 13:25
Weekly Report: what happened at VVOS last week (1102-1106)?
Weekly Report · 11/09 09:00
Weekly Report: what happened at VVOS last week (1026-1030)?
Weekly Report · 11/02 09:00
Weekly Report: what happened at VVOS last week (1019-1023)?
Weekly Report · 10/26 09:00
Vivos Therapeutics Regains Nasdaq Compliance After Equity Boost
TipRanks · 10/21 11:29
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Barchart · 10/20 10:40
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 10/20 08:43
Vivos Therapeutics Acquires Stake in SOD Sciences IP
TipRanks · 10/19 21:20
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M
Benzinga · 10/19 21:07
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 10/19 21:05
Press Release: Vivos Therapeutics Closes -2-
Dow Jones · 10/19 21:01
Weekly Report: what happened at VVOS last week (1012-1016)?
Weekly Report · 10/19 09:00
More
Webull provides a variety of real-time VVOS stock news. You can receive the latest news about Vivos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.